Comparative efficacy evaluation of two modified-live PRRS vaccines

摘要

The swine industry continues to experience significant losses due to PRRS virus infections of sow farms and growing pigs.1 Modified-live vaccine (MLV) can significantly reduce PRRSV induced lung lesions following a heterologous challenge.2 In addition, it has been demonstrated that the implementation of a systematic methodology for PRRS control that utilizes modified-live vaccine for the control of wild type-PRRSV infections can mitigate the consequences of infection on health and performance.3'1 Itis necessary for modified-live vaccines to be effective against heterologous challenge with current PRRSV field isolates. The objective of this study was to directly compare the efficacy of Ingelvac PRRS~R MLV (BIVI-Boehringer Ingelheim Vetmedica, Inc.,St. Joseph, MO) and Prime Pac~ PRRS + (Merck Animal Health, Omaha, NE) against a heterologous PRRSV challenge in a standard respiratory challenge model in growing pigs.